ProMIS Neurosciences News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

13.05.20	ProMIS Neurosciences Announces First Quarter 2020 Results (GlobeNewswire)
12.05.20	ProMIS Neurosciences identifies multiple novel targets on SARS CoV-2 for development of a highly accurate COVID-19 antibody test (GlobeNewswire)
06.05.20	ProMIS Neurosciences develops novel antagonists for RACK1, a protein involved in numerous neurodegenerative diseases, including ALS (GlobeNewswire)
30.04.20	ProMIS Neurosciences creates novel intrabodies for ALS, frontotemporal dementia and other neurodegenerative diseases (GlobeNewswire)
22.04.20	ProMIS Neurosciences commends Biogen for clarifying aducanumab regulatory filing (GlobeNewswire)
15.04.20	ProMIS Neurosciences announces collaboration to develop serological test to assess COVID-19 immunity (GlobeNewswire)
09.04.20	Journal of the American Academy of Neurology Publishes ProMIS Neurosciences’ Abstracts on Novel Antibody Candidates (GlobeNewswire)
07.04.20	ProMIS Neurosciences to Present Data and Moderate Session at AAIC 2020 (GlobeNewswire)
24.03.20	PROMIS NEUROSCIENCES ANNOUNCES APPROVAL FOR WARRANT REPRICING (GlobeNewswire)
18.03.20	ProMIS Neurosciences Announces Fiscal Year 2019 Annual Results (GlobeNewswire)
26.02.20	ProMIS Neurosciences Initiates Natural History Study of Blood-Based Biomarkers in Alzheimer’s Disease (GlobeNewswire)
25.02.20	ProMIS Neurosciences Announces Gross Proceeds of $1,257,970 Related to the Exercise of Common Stock Warrants (GlobeNewswire)
11.02.20	ProMIS Neurosciences to Participate in Noble Capital Markets 16th Annual Investor Conference (GlobeNewswire)
06.02.20	ProMIS Neurosciences to Participate in the BIO CEO & Investor Conference (GlobeNewswire)
29.01.20	ProMIS Neurosciences Data for Alzheimer’s Disease Program Targeting Tau Accepted for Presentation at Tau2020 (GlobeNewswire)
15.01.20	ProMIS Neurosciences Appoints Dr. José Luis Molinuevo to its Scientific Advisory Board (GlobeNewswire)
09.01.20	ProMIS Neurosciences to present at Sachs 3rd Annual Neuroscience Innovation Forum (GlobeNewswire)
08.01.20	ProMIS Neurosciences issues Chairman’s Update detailing positive outlook for Alzheimer’s disease therapy, pipeline in 2020 (GlobeNewswire)
31.12.19	ProMIS Neurosciences Completes Second Closing of Private Placement (GlobeNewswire)
10.12.19	ProMIS Neurosciences’ Alzheimer’s disease program takes on renewed significance following positive aducanumab news (GlobeNewswire)
05.12.19	Aducanumab is good; next generation Alzheimer’s disease therapies will be better (GlobeNewswire)
18.11.19	ProMIS Neurosciences Completes First Closing of Private Placement (GlobeNewswire)
14.11.19	ProMIS Neurosciences Announces Third Quarter 2019 Results (GlobeNewswire)
13.11.19	ProMIS Neurosciences Undertaking $6.5M Private Placement (GlobeNewswire)
07.11.19	ProMIS Neurosciences Outlines Best-in-class Approach to Amyloid-beta-targeting Drug Candidates for Alzheimer’s Disease (GlobeNewswire)
23.10.19	ProMIS Neurosciences advances ALS program selectively targeting toxic form of TDP-43 (GlobeNewswire)
17.10.19	ProMIS Neurosciences advances Alzheimer’s disease program targeting neurotoxic forms of tau (GlobeNewswire)
08.10.19	ProMIS Neurosciences Identifies Novel Antibody Candidates for Multiple System Atrophy (GlobeNewswire)
16.09.19	ProMIS Neurosciences Executive Chairman Eugene Williams to Speak on Panel at Fall Investor Summit (GlobeNewswire)
03.09.19	ProMIS Neurosciences to Present at H.C. Wainwright Investor Conference (GlobeNewswire)
27.08.19	ProMIS Neurosciences Appoints Internationally Recognized Researcher in Alzheimer’s Disease in Down Syndrome Dr. Andre Strydom to its Scientific Advisory Board (GlobeNewswire)
13.08.19	ProMIS Neurosciences Announces Second Quarter 2019 Results (GlobeNewswire)
24.07.19	ProMIS Neurosciences Announces Results of Annual Meeting of Shareholders (GlobeNewswire)
18.07.19	ProMIS Neurosciences Highlights Data for PMN310 at AAIC 2019 (GlobeNewswire)
10.07.19	ProMIS Neurosciences to Present Data at 2019 Alzheimer’s Association International Conference (GlobeNewswire)
09.07.19	ProMIS Neurosciences’ Data for Alzheimer’s Disease Clinical Candidate PMN310 Published in Scientific Reports (GlobeNewswire)
26.06.19	ProMIS Neurosciences Closing Private Placement (GlobeNewswire)
19.06.19	ProMIS Neurosciences Appoints Renowned Parkinson’s Disease Expert Dr. C. Warren Olanow to Scientific Advisory Board (GlobeNewswire)
05.06.19	ProMIS Neurosciences Presents Lead Program for Alzheimer’s Disease at Prestigious Keystone Symposia Scientific Conference (GlobeNewswire)
29.05.19	ProMIS Neurosciences’ Eugene Williams to Present at JLABS’ Conference on Innovations in Neurodegenerative Diseases (GlobeNewswire)
28.05.19	ProMIS Neurosciences Identifies Novel Antibodies for Alzheimer’s Disease with Selectivity for the Neurotoxic Form of Tau (GlobeNewswire)
14.05.19	ProMIS Neurosciences Announces First Quarter 2019 Results (GlobeNewswire)
23.04.19	ProMIS Neurosciences to Participate in the Think Equity Investor Conference (GlobeNewswire)
26.03.19	ProMIS Neurosciences to Participate in Microcap Spring Investor Summit 2019 (GlobeNewswire)
21.03.19	Aducanumab Failure: Selectivity for the Toxic Oligomer is Essential to Treating Root Cause of Alzheimer’s Disease (GlobeNewswire)
19.03.19	ProMIS Neurosciences to Present Data for Potential Best-in-Class Antibody Candidates for Parkinson’s Disease at AD/PD™ 2019 Conference (GlobeNewswire)
15.03.19	ProMIS Neurosciences Announces Fiscal Year 2018 Annual Results (GlobeNewswire)
21.02.19	ProMIS Neurosciences Adds Pharmaceutical Leader Timothy Rothwell to Board of Advisors (GlobeNewswire)
12.02.19	Parkinson’s Disease: ProMIS Neurosciences Identifies Several Antibody Drug Candidates Showing Best-in-Class Selectivity for Toxic Forms of Alpha-Synuclein Compared to other Therapeutic Antibodies in D (GlobeNewswire)
31.01.19	Selectivity for the Toxic Oligomer Essential to Treating Root Cause of Alzheimer’s Disease (GlobeNewswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

ABB	50.28	1.62 %	K V
UBS Group	28.48	1.42 %	K V
CieFinRichemont	122.70	1.24 %	K V
Lonza Grp	526.40	1.15 %	K V
Part Grp Hldg	1’280.00	1.11 %	K V
Sonova Hldg	300.80	-0.07 %	K V
Sika	228.10	-0.09 %	K V
Novartis	93.27	-0.12 %	K V
Nestle	76.48	-0.21 %	K V
Swisscom	508.50	-0.29 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu ProMIS Neurosciences Inc

Aktien Top/Flop

Meistgelesene Nachrichten